Last updated on July 2019

Study to Investigate the Safety Tolerability and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

Brief description of study

This is a Phase Ib, randomized double-blind, placebo-controlled multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of DSTA4637S when given in addition to anti-staphylococcal SOC antibiotics to participants with methicillin-resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus aureus (MSSA) bacteremia requiring at least 4 weeks of anti-staphylococcal SOC antibiotics.

Clinical Study Identifier: NCT03162250

Find a site near you

Start Over

Hospital Universitario de Bellvitge

Hospitalet de Llobregat, Spain
  Connect »

Hospital Clinic de Barcelona

Barcelona, Spain
  Connect »

Hospital del Mar

Barcelona, Spain
  Connect »